Brentuximab Vedotin for Steroid Refractory GvHD

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2016

Conditions

Graft vs. Host Disease

Interventions

DRUG

Brentuximab Vedotin

Starting dose is 0.6 mg/kg weekly x 3

Trial Locations (5)

Massachusetts General Hospital, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Memorial Sloan Kettering Cancer Center, New York

Ohio State University, Columbus

All Listed Sponsors

collaborator

Seagen Inc.

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01596218 - Brentuximab Vedotin for Steroid Refractory GvHD | Biotech Hunter | Biotech Hunter